Pilot Payer-Provider CollaborationsVideo Categories: Payer-Provider
Emily Knight presents why quality of life is a big issue in polycythemia vera and how she helps patients in management Supported through funding from Incyte
Dr. David S. Siegel discusses the importance of understanding the molecular biology of myeloma. Physicians can now look at and offer alternative treatments to patients that they identify will most likely do poorly with traditional treatment. He believes this area will develop quickly over the next 2 to 5 years.